Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 2)
NCT04510818
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Head and Neck Cancer
Esophageal Squamous Cancer
Interventions
DRUG:
Capecitabine, Camrelizumab
Sponsor
Ruijin Hospital